Menu Search
Equities

PhoenixBio Co Ltd

6190:TYO

PhoenixBio Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)460.00
  • Today's Change0.00 / 0.00%
  • Shares traded9.70k
  • 1 Year change-18.29%
  • Beta0.7418
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year PhoenixBio Co Ltd's revenues fell -19.24% from 2.12bn to 1.72bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 493.33m to 26.38m, a -94.65% decrease.
Gross margin72.57%
Net profit margin0.43%
Operating margin0.51%
Return on assets0.25%
Return on equity0.43%
Return on investment0.36%
More ▼

Cash flow in JPYView more

In 2024, cash reserves at PhoenixBio Co Ltd fell by 170.43m. However, Cash Flow from Investing totalled 115.36m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 79.31m for operations while cash used for financing totalled 244.88m.
Cash flow per share8.48
Price/Cash flow per share56.73
Book value per share456.80
Tangible book value per share453.14
More ▼

Balance sheet in JPYView more

PhoenixBio Co Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.74% of the market capitalization can be attributed to its 1.38bn and debt could be paid in full if management chose.
Current ratio4.91
Quick ratio3.89
Total debt/total equity0.25
Total debt/total capital0.20
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.